

Docket No.: 176/60792 (6-11415-868)

TATES PATENT AND TRADEMARK ÓFFICE

Applicant: Mahin D. Maines

Serial No. : 09/606,129

Filed

: June 28, 2000

For

BILIVERDIN REDUCTASE FRAGMENTS AND VARIANTS, AND

METHODS OF USING BILIVERDIN REDUCTASE AND SUCH

FRAGMENTS AND VARIANTS

TRANSMITTAL LETTER

Assistant Commissioner For Patents Washington, D.C. 20231

Box: Missing Parts

Dear Sir:

In response to the Notice to File Missing Parts of Application Under 37 CFR 1.53(d), which was mailed by the United States Patent and Trademark Office on August 18, 2000, enclosed are:

- [X] A Request for Two-Month Extension of Time.
- A Combined Declaration and Power of Attorney.
- [X] Submission of Revised Sequence Listing and Statement in Accordance With 37 CFR § 1.821(g), 3.5" diskette, and a copy of the revised Sequence Listing (21 pages).
- A verified statement to establish small entity status under 37 CFR 1.9 and 1.27. [X]
- A Request for Corrected Filing Receipt and Copy of Official Filing Receipt. [X]
- [X]A copy of the Notice to File Missing Parts.
- A self-addressed, prepaid postcard for acknowledging receipt.
- [X] Fees as calculated below:

FEE FOR TWO-MONTH EXTENSION OF TIME	\$195.00
SURCHARGE 37 CFR 1.16(e)	\$65.00
ADDITIONAL FEES	\$
TOTAL FEES SUBMITTED HEREWITH	\$260.00

A check in the amount of \$65.00 and a check in the amount of \$195.00 to cover the [X] above fees.

[X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 14-1138. A duplicate copy of this sheet is enclosed.

Date: Jecember 18, 2000.

Edwin V. Merkel

Registration No. 40,087

Nixon Peabody LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603 Telephone: (716) 263-1128 Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8 (a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231. on the

Date

Wendy L. Harrold



FORMALITIES LETTER *OC000000005335488*



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 2023 I

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
			•

09/606,129

06/28/2000

Mahin D. Maines

176/60792(6-11415-868)

Michael L Goldman Nixon Peabody LLP Clinton Square P O Box 31051 Rochester, NY 14603



Date Mailed: 08/18/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- · Small Entity Statement is missing.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 1.825 for the following reason(s):
 - The computer readable form that has been filed with the application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- Patentin Software Program Support
- - For Technical Assistance, call (703) 287-0200
- - To Purchase Patentin Software, call (703) 306-2600
- The balance due by applicant is \$ 976.

A copy of this notice <u>MUST</u> be returned with the reply.

M. May

12/27/2000 ETULU1

00000055 09606129

02 FC:205

65.00 OP

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT 176/60792 (6-11415-868)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mahin D. Maines **Applicant** 09/606,129

Examiner: Unknown

Serial No

Art Unit: 1646

Filed

For

June 28, 2000

BILIVERDIN REDUCTASE FRAGMENTS)

AND VARIANTS, AND METHODS OF USING BILIVERDIN REDUCTASE AND SUCH FRAGMENTS AND VARIANTS

REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination **Customer Service Center** Washington, D.C. 20231

Dear Sir:

Applicant hereby requests a corrected filing receipt for the aboveidentified application. On the enclosed copy of the official filing receipt, the entity status is omitted. It should read "SMALL ENTITY", per the small entity declaration being filed with the enclosed Response to Notice to File Missing Parts.

Since Applicant is not responsible for this error, no fee is enclosed.

Respectfully submitted,

Dated: <u>December 18</u>, 2000

Edwin V. Merkel

Registration No. 40,087

Nixon Peabody LLP

Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051

Telephone: (716) 263-1128 Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8 (a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.G.

date below. 18/00

Dato

Wendy L. Harrold





FILING RECEIPT *OC000000005335487*



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: ASSISTANT SECRETARY AND

COMMISSIONER OF PATENT AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/606 129	06/28/2000	1646	846 1	76/60792/6-1141	5-868)	23 67	

Michael L Goldman Nixon Peabody LLP Clinton Square P O Box 31051 Rochester, NY 14603



Date Mailed: 08/18/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Mahin D. Maines, Rochester, NY;

Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/141,309 06/28/1999 WHICH CLAIMS BENEFIT OF 60/163,223 11/03/1999

Foreign Applications

If Required, Foreign Filing License Granted 08/18/2000

- XSMALL ENTITY

Title

Biliverdin reductase fragments and variants, and methods of using biliverdin reductase and such fragments and variants

Preliminary Class

514

Data entry by : MAY, MOLIKI

Team: OIPE

Date: 08/18/2000



GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFF 5.15. The scope and limitations of this license are set forth in 37 CFF 5.15(a) unless an earlier license has been issued under 37 CFF 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFF 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the
 Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt
 along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231